

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(use ~~as~~ many sheets ~~as~~ necessary)

<b>Application Number</b>	10/530,215
<b>Filing Date</b>	April 4, 2005
<b>First Named Inventor</b>	Dooseop Kim, et al
<b>Group Art Unit</b>	1624
<b>Examiner Name</b>	

Sheet	1	of	4	Attorney Docket Number	21239YP
-------	---	----	---	------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/MB/	1	PCT	WO 97/40832		Hans-Knoll-Institut Fur Naturstoff-Forschung	11/06/1997
	2	PCT	WO 98/19998		Novartis AG	05/14/1998
	3	PCT	WO 00/34241		Novartis AG	06/15/2000
	4	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
	5	PCT	WO 01/42262 A2		Akzo Nobel N.V.	06/14/2001
	6	PCT	WO 01/96295 A2		Novartis AG	12/20/2001
	7	PCT	WO 02/02560 A2		Novo Nordisk A/S	01/10/2002
	8	PCT	WO 02/076450 A1		Merck & Co., Inc.	10/03/2002
	9	PCT	WO 03/000180 A2		Merck & Co., Inc.	01/03/2003
/MB/	10	PCT	WO 03/000181 A2		Merck & Co., Inc.	01/03/2003

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/530,215
				Filing Date	April 4, 2005
				First Named Inventor	Dooseop Kim, et al.
				Group Art Unit	1624
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	21239YP

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/MB/	11	PCT	WO 03/004498 A1		Merck & Co., Inc.	01/16/2003
	12	PCT	WO 03/082817 A2		Merck & Co., Inc.	10/09/2003
	13	PCT	WO 2004/007468 A1		Merck & Co., Inc.	01/22/2004
	14	PCT	WO 2004/032836 A2		Merck & Co., Inc.	04/22/2004
	15	PCT	WO 2004/043940 A1		Merck & Co., Inc.	05/27/2004
	16	PCT	WO 2004/05022 A2		Merck & Co., Inc.	06/17/2004
	17	PCT	WO 2004/058266 A1		Merck & Co., Inc.	07/15/2004
	18	PCT	WO 2004/064778 A2		Merck & Co., Inc.	08/05/2004
	19	PCT	WO 2004/069162 A2		Merck & Co., Inc.	08/19/2004
/MB/	20	PCT	WO 2004/110436 A1		Merck & Co., Inc.	12/23/2004

Examiner Signature	/Mark Berch/ (10/19/2007)	Date Considered	
-----------------------	---------------------------	--------------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Attorney Docket Number 21239YP[illegible][illegible]

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/530,215	
			Filing Date	April 4, 2005	
			First Named Inventor	Dooseop Kim, et al	
			Group Art Unit	1624	
Examiner Name					
Sheet	4	of	4	Attorney Docket Number	21239YP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/MB/	1	Augustyns, K. et al., "Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 13, No. 4, pp. 499-510, 2003
	2	Deacon, C. F. et al., "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?" Expert Opin. Investig. Drugs, Vol. 13, No. 9, pp. 1091-1102, 2004
	3	Deacon, C. F., "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1" Diabetes, Vol. 53, pp. 2181-2189, 2004
	4	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes" Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp. 87-100, 2003
	5	Holst, J. J., "Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors" Expert Opin. Emerg. Drugs, Vol. 9, No. 1, pp. 155-166, 2004
	6	Holst, J. J. et al., "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus" Current Opinion in Pharmacology, Vol. 4, pp. 589-596, 2004
	7	Knudsen, L. B., "Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" J. Med. Chem, Vol. 47, pp 4128-4134, 2004
	8	Stockel-Maschek, A. et al., "Potent Inhibitors of Dipeptidyl Peptidase IV and their Mechanisms of Inhibition" Cellular Peptidases in Immune Functions and Diseases 2, Vol. 477, pp. 117-123, 2000
	9	Novartis AG: WO0034241 "Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus" Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp. 1937-1942, 2000
	10	Vahl, T. P. et al., "Gut peptides in the treatment of diabetes mellitus" Expert Opin. Investig. Drugs, Vol. 13, No. 3, pp. 177-188, 2004
/MB/	11	Weber, A. E., "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem., Vol. 47, pp. 4135-4141, 2004

Examiner Signature	/Mark Berch/ (10/19/2007)	Date Considered	
--------------------	---------------------------	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

### STATEMENT BY APPLICANT

6/23/05

**COMPLETE IF KNOWN**

Attorney Docket Number	21239YP
------------------------	---------

## Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## INFORMATION DISCLOSURE

### STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

Application Number 10/530,215

<b>Filing Date</b>	April 4, 2005
--------------------	---------------

<b>First Named Inventor</b>	Dooseop Kim, et al.
-----------------------------	---------------------

### Group Art Unit

Examiner Name

Attorney Docket Number 21239YP

Sheet

2

of

4

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/MB/	18	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
	19	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
	20	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
	21	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001
	22	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
	23	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
	24	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
	25	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
	26	PCT	WO 97/40832		Hansknoll-Institut Für Naturstoff-Forschung E.V.	11/06/1997
/MB/	27	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

/Mark Berch/ (10/19/2007)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

*(use as many sheets as necessary)*

Sheet

3

of

4

Attorney Docket Number

21239YP

**COMPLETE IF KNOWN****Application Number**

10/530,215

**Filing Date**

April 4, 2005

**First Named Inventor**

Dooseop Kim, et al.

**Group Art Unit**

Examiner Name

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/MB/	28	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002
	29	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
	30	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
	31	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004
	32	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
	33	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
	35	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
/MB/	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005

**Examiner  
Signature**

/Mark Berch/ (10/19/2007)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE**

## **STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	10/530,215
Filing Date	April 4, 2005
First Named Inventor	Dooseop Kim, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21239YP

Sheet 4 of 4

### **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/MB/	37	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.
	38	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.
	39	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.
	40	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.
	41	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol.12, 2004, pages 87-100.
	42	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.
	43	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4128-4134.
	44	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4135-4141.
	45	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.
/MB/	46	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.

Examiner Signature

/Mark Berch/ (10/19/2007)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003



**COMPLETE IF KNOWN**

<b>Application Number</b>	<b>10/530,215</b>
---------------------------	-------------------

<b>Filing Date</b>	April 4, 2005
--------------------	---------------

<b>First Named Inventor</b>	Dooseop Kim, et al
-----------------------------	--------------------

Group Art Unit	1624
----------------	------

**Examiner Name**

Attorney Docket Number 21239YP

1

of

4

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Date Considered

Computer generated form "IDS Form" (IDS Folder), Merrick & Co., Inc., 06/28/2007

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/530,215
<b>Filing Date</b>	April 4, 2005
<b>First Named Inventor</b>	Dooseop Kim, et al.
<b>Group Art Unit</b>	1624
<b>Examiner Name</b>	

Sheet	2	of	4	Attorney Docket Number	21239YP
-------	---	----	---	------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/MB/	11	PCT	WO 03/004498 A1		Merck & Co., Inc.	01/16/2003
	12	PCT	WO 03/082817 A2		Merck & Co., Inc.	10/09/2003
	13	PCT	WO 2004/007468 A1		Merck & Co., Inc.	01/22/2004
	14	PCT	WO 2004/032836 A2		Merck & Co., Inc.	04/22/2004
	15	PCT	WO 2004/043940 A1		Merck & Co., Inc.	05/27/2004
	16	PCT	WO 2004/05022 A2		Merck & Co., Inc.	06/17/2004
	17	PCT	WO 2004/058266 A1		Merck & Co., Inc.	07/15/2004
	18	PCT	WO 2004/064778 A2		Merck & Co., Inc.	08/05/2004
	19	PCT	WO 2004/069162 A2		Merck & Co., Inc.	08/19/2004
/MB/	20	PCT	WO 2004/110436 A1		Merck & Co., Inc.	12/23/2004

**Examiner  
Signature**

/Mark Berch/ (10/19/2007)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

10/530,215

**April 4, 2005**

Dooseop Kim, et al.

1624

1

Sheet

3

of

4

Attorney Docket Number

21239YP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

/Mark Berch/ (10/19/2007)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/530,215	
			Filing Date	April 4, 2005	
			First Named Inventor	Dooseop Kim, et al	
			Group Art Unit	1624	
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	21239YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/MB/	1	Augustyns, K. et al., "Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 13, No. 4, pp. 499-510, 2003
	2	Deacon, C. F. et al., "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?" Expert Opin. Investig. Drugs, Vol. 13, No. 9, pp. 1091-1102, 2004
	3	Deacon, C. F., "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1" Diabetes, Vol. 53, pp. 2181-2189, 2004
	4	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes" Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp. 87-100, 2003
	5	Holst, J. J., "Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors" Expert Opin. Emerg. Drugs, Vol. 9, No. 1, pp. 155-166, 2004
	6	Holst, J. J. et al., "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus" Current Opinion in Pharmacology, Vol. 4, pp. 589-596, 2004
	7	Knudsen, L. B., "Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" J. Med. Chem, Vol. 47, pp 4128-4134, 2004
	8	Stockel-Maschek, A. et al., "Potent Inhibitors of Dipeptidyl Peptidase IV and their Mechanisms of Inhibition" Cellular Peptidases in Immune Functions and Diseases 2, Vol. 477, pp. 117-123, 2000
	9	Novartis AG: WO0034241 "Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus" Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp. 1937-1942, 2000
	10	Vahl, T. P. et al., "Gut peptides in the treatment of diabetes mellitus" Expert Opin. Investig. Drugs, Vol. 13, No. 3, pp. 177-188, 2004
/MB/	11	Weber, A. E., "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem., Vol. 47, pp. 4135-4141, 2004

Examiner Signature	/Mark Berch/ (10/19/2007)	Date Considered	
--------------------	---------------------------	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007